Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

361
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
361
Inhaled Medications01:23

Inhaled Medications

801
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
801
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

295
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
295
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

258
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
258
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

216
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
216
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

359
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
359

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Influence of strontium ions incorporated into nanosheet-pore topographical titanium substrates on osteogenic differentiation of mesenchymal stem cells <i>in vitro</i> and on osseointegration <i>in vivo</i>.

Journal of materials chemistry. B·2026
Same author

Correction: Nanosheet-pore topographical titanium substrates: a biophysical regulator of the fate of mesenchymal stem cells.

Journal of materials chemistry. B·2026
Same author

Water-Splitting-Suppressed High-Capacity Bipolar Electrodes Enabled by Topochemical Electron Buffering for Symmetric Aqueous Batteries.

Angewandte Chemie (International ed. in English)·2026
Same author

Hybrid Seeding-Template Modulation of Sn-Pb Perovskite Crystallization for High-Efficiency All-Perovskite Tandem Solar Cells.

Angewandte Chemie (International ed. in English)·2026
Same author

Toward developing a patient reported outcomes measure for children with heart failure: A qualitative study design.

American heart journal·2026
Same author

Polystyrene nanoparticles stimulate the growth and microcystin synthesis of Microcystis aeruginosa.

Aquatic toxicology (Amsterdam, Netherlands)·2026

Related Experiment Video

Updated: Feb 3, 2026

Breath Collection from Children for Disease Biomarker Discovery
06:09

Breath Collection from Children for Disease Biomarker Discovery

Published on: February 14, 2019

7.4K

Children and Adults With Rare Diseases Need Innovative Medical Devices.

Vasum Peiris1, Kui Xu2, Heather L Agler3

  • 1Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Avenue, WO Building 66, Suite 5422, Silver Spring, MD 20993.

Journal of Medical Devices
|November 7, 2018
PubMed
Summary

Physicians report a significant need for innovative medical devices for rare diseases (RD), especially for children. Over 850 device needs were identified, highlighting a public health priority for accelerated development.

More Related Videos

Measuring Attentional Biases for Threat in Children and Adults
08:25

Measuring Attentional Biases for Threat in Children and Adults

Published on: October 19, 2014

15.8K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.4K

Related Experiment Videos

Last Updated: Feb 3, 2026

Breath Collection from Children for Disease Biomarker Discovery
06:09

Breath Collection from Children for Disease Biomarker Discovery

Published on: February 14, 2019

7.4K
Measuring Attentional Biases for Threat in Children and Adults
08:25

Measuring Attentional Biases for Threat in Children and Adults

Published on: October 19, 2014

15.8K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.4K

Area of Science:

  • Medical device innovation
  • Rare disease management
  • Pediatric healthcare technology

Background:

  • Rare diseases (RD) affect 30 million Americans, with half being children.
  • Existing medical devices often inadequately address the complex needs of RD patients.
  • There is a critical gap in understanding the specific device requirements for RD care.

Purpose of the Study:

  • To comprehensively evaluate the unmet medical device needs for rare disease management.
  • To identify and document specific diagnostic and therapeutic device requirements.
  • To quantify the unmet need and inform medical device stakeholders.

Main Methods:

  • A cross-sectional survey of physicians with expertise in rare diseases was conducted.
  • Participants were drawn from FDA committees, Pediatric Device Consortia, and NIH Rare Diseases Clinical Research Network.
  • Data collected focused on perceived needs for innovative medical devices for RD.

Main Results:

  • 90% of eligible physicians confirmed the need for innovative devices for RD care.
  • Over 850 distinct device needs were identified across 436 rare diseases.
  • 74% of identified needs were specifically for pediatric rare diseases.
  • Pediatric physicians and those with more RD experience reported higher dissatisfaction with current devices.

Conclusions:

  • A substantial public health need exists for novel medical devices for both pediatric and adult rare disease patients.
  • Creating entirely new devices is the primary recommendation to address these unmet needs.
  • Collaboration between regulatory bodies (FDA, NIH) and developers is crucial to accelerate device innovation for vulnerable populations.